Caplyta Demonstrates Rapid Mania Symptom Reduction in Bipolar I Disorder Trial

Johnson & Johnson's (JNJ) Caplyta (lumateperone) has shown improved symptoms in patients experiencing manic episodes linked to bipolar I disorder. The Phase 3 study evaluated once-daily 42mg doses of Caplyta against placebo over a three-week duration, demonstrating statistically significant and rapid reduction in manic symptoms compared to placebo at Week 3.

The trial met its primary endpoint, with participants receiving Caplyta achieving a 4.8-point greater reduction in Young Mania Rating Scale total scores compared to placebo at Week 3. Notably, these gains were sustained from Day 3 onward.

Michael Thase, a professor at the University of Pennsylvania, commented on the results: 'These results are encouraging because CAPLYTA not only significantly improved the symptoms of mania, but did so as early as Day 3, with benefits sustained through Week 3, supporting its potential to meaningfully advance how we treat acute mania in bipolar I disorder.'

The safety profile of Caplyta was also favorable, demonstrating low discontinuation rates and matching its established safety profile.